For patients with intermediate-risk prostate cancer, those with lower apparent diffusion coefficient (ADC) values on pre-treatment DWI MRI had a fourfold higher prevalence of distant metastasis in a study with a 10.3-year median follow-up.
|Articles|May 13, 2008
Toshiba showcases Vegas-based AquilionOne
Attendees of the International Symposium on Multidetector-Row CT will get a chance to visit a clinical installation of Toshiba’s new 320-channel CT scanner at the nearby Nevada Imaging Centers in Las Vegas.
Advertisement
Attendees of the International Symposium on Multidetector-Row CT will get a chance to visit a clinical installation of Toshiba's new 320-channel CT scanner at the nearby Nevada Imaging Centers in Las Vegas. The scanner, whose 16-cm wide area detector covers whole organs and records dynamic functions in the brain and heart, is the first AquilionOne to be installed in the Western U.S.
Advertisement
Related to this article
In the second of a two-part podcast episode, Lauren Nicola, MD, Christoph Wald, MD, PhD, MBA, and Peter Shen discuss challenges with evaluating value and ROI for AI software, the physician time required to do so, and possible solutions to facilitate improved clarity and consistency with AI reimbursement.
In the latest episode of her “Breast Imaging in Focus” series, Manisha Bahl, MD, MPH, FSBI, offer pertinent takeaways for breast radiologists from recently issued guidelines for addressing proliferative breast lesions with atypia and lobular carcinoma in situ (LCIS).
In a study involving over 2,800 people who had brain MRI scans, researchers found that people in the most disadvantaged neighborhoods had 37 percent higher white matter hyperintensity volume (WMHV) on average in comparison to people in the least disadvantaged areas.
In the second of a two-part interview, Kalpana Kanal, PhD, and Mahadevappa Mahesh, MS, PhD, FAPPM, FACR, discussed future directions for research on CT radiation dosing, including the potential of indication-specific diagnostic reference levels (DRLs).
Amid the explosion of imaging volume, an emerging silver lining is increasing recognition from referring clinicians of the time and value radiologists provide to facilitate patient care.
In a recent episode of our Molecular Imaging in Focus series, Thomas Hope, MD, discussed challenges with conventional imaging for gliomas and the potential of the newly FDA-approved PET agent floretyrosine F18 (18F-FET) for differentiating between glioma progression and treatment-related effects.
Catch up on the top radiology content of the past week.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Brain MRI Study Reveals Higher Brain Age Gap and White Matter Hyperintensity for Those in Disadvantaged Neighborhoods
2
The Reading Room Podcast: Assessing the Current Landscape of AI and Reimbursement in Radiology, Part 2
3
Breast Imaging in Focus: Key Pearls from New Guidelines on Proliferative Breast Lesions with Atypia and LCIS
4
Molecular Imaging in Focus: Can the Newly FDA-Approved PET Agent Floretyrosine F18 Have an Impact for Glioma Imaging?
5